|
|
||||||||
Experimental Therapeutics Branch, IRP (Dr.s Gopinathan, Teräväinen, Ward, and Calne), and the Office of Biometry and Field Studies (Dr. Dambrosia), NINCDS, and the Laboratory of Neurophysiology (Drs. Sanes, Stuart, and Evarts), NIMH, Bethesda, MD
we studied the actions of lisuride, a dopaminergic ergot derivative, in 20 parkinsonian patients. When the dose was increased gradually, most patients tolerated up to 5 mg daily. Clinical assessment and objective, computer-assisted evaluation revealed improvement in akinesia, rigidity and tremor. Adverse reactions were similar to those seen with levodopa and bromocriptine, but somnolence tended to occur more often with lisuride.
Address correspondence and reprint requests to Dr. Calne, Clinical Director, NINCDS, Building 10, Room 6D20, National Institutes of Health, Bethesda, MD 20205.
Accepted for publication June 17, 1980.
This article has been cited by other articles:
![]() |
Habib-ur-Rehman Diagnosis and Management of Tremor Arch Intern Med, September 11, 2000; 160(16): 2438 - 2444. [Abstract] [Full Text] |
||||
![]() |
N. C. Reynolds Jr and G. K. Montgomery Factor Analysis of Parkinson's Impairment: An Evaluation of the Final Common Pathway Arch Neurol, October 1, 1987; 44(10): 1013 - 1016. [Abstract] [PDF] |
||||
![]() |
F. White and J. Appel Lysergic acid diethylamide (LSD) and lisuride: differentiation of their neuropharmacological actions Science, April 30, 1982; 216(4545): 535 - 537. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |